January 2021


Tucatinib | Colorectal Cancer | TPS153

MOUNTAINEER TIP: Open-Label, Phase 2 Study of Tucatinib Combined with Trastuzumab for HER2-Positive Metastatic Colorectal Cancer (Trial in Progress)

SEA-CD40 | Pancreatic Ductal Adenocarcinoma | TPS451

SGNS40-001 TIP: Phase 1 study of SEA-CD40, gemcitabine, nab-paclitaxel, and pembrolizumab in patients (pts) with metastatic pancreatic ductal adenocarcinoma (PDAC) (Trial in Progress)

Tucatinib | Urothelial Carcinoma | Abstract TPS499

MOUNTAINEER-02 TIP: Phase 2/3 study of tucatinib, trastuzumab, ramucirumab, and paclitaxel in previously treated HER2+ gastric or gastroesophageal junction adenocarcinoma: Trial in Progress

Ladiratuzumab vedotin | Prostate Cancer | Abstract TPS185

SGNLVA-005 TIP: Open-Label, Phase 2 Study of Ladiratuzumab Vedotin (LV) for Advanced Gastric and Gastroesophageal Junction Adenocarcinoma (SGNLVA-005, Trial in Progress)